Evidence map›Paper›PMID 18579589›Full record

ArticleJournal of virology2008

Human papillomavirus type 16 E7 oncoprotein associates with E2F6.

Margaret E McLaughlin-Drubin, Kyung-Won Huh, Karl Münger

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 126 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Margaret E McLaughlin-DrubinDepartment of Medicine, Infectious Diseases Division, The Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Kyung-Won Huh
Karl Münger
Brigham and Women's Hospital · USHarvard University · US

Funding

BIOLOGICAL ACTIVITY OF HPV E7 IN HUMAN EPITHELIAL CELLSR01CA066980 · NCI · TUFTS UNIVERSITY BOSTON · PI MUNGER, KARL · 1996 to 2019
$7.4M
MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7R01CA081135 · NCI · TUFTS UNIVERSITY BOSTON · PI MUNGER, KARL · 2000 to 2014
$4.2M
Role of HPV16 E7/E2F6 interaction in viral oncogenesisF32CA121771 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MCLAUGHLIN-DRUBIN, MARGARET ERIN · 2006 to 2006
$50k
NCI NIH HHS CA066980NCI NIH HHS CA081135NCI NIH HHS F32 CA121771NCI NIH HHS R01 CA066980NCI NIH HHS R01 CA081135
6 · The paper itself

Abstract

The papillomavirus life cycle is intimately coupled to the differentiation state of the infected epithelium. Since papillomaviruses lack most of the rate-limiting enzymes required for genome synthesis, they need to uncouple keratinocyte differentiation from cell cycle arrest and maintain or reestablish a replication-competent state within terminally differentiated keratinocytes. The human papillomavirus (HPV) E7 protein appears to be a major determinant for this activity and induces aberrant S-phase entry through the inactivation of the retinoblastoma tumor suppressor and related pocket proteins. In addition, E7 can abrogate p21 and p27. Together, this leads to the activation of E2F1 to E2F5, enhanced expression of E2F-responsive genes, and increased cdk2 activity. E2F6 is a pRB-independent, noncanonical member of the E2F transcription factor family that acts as a transcriptional repressor. E2F6 expression is activated in S phase through an E2F-dependent mechanism and thus may provide a negative-feedback mechanism that slows down S-phase progression and/or exit in response to the activation of the other E2F transcription factors. Here, we show that low- and high-risk HPV E7 proteins, as well as simian virus 40 T antigen and adenovirus E1A, can associate with and inactivate the transcriptional repression activity of E2F6, thereby subverting a critical cellular defense mechanism. This may result in the extended S-phase competence of HPV-infected cells. E2F6 is a component of polycomb group complexes, which bind to silenced chromatin and are critical for the maintenance of cell fate. We show that E7-expressing cells show decreased staining for E2F6/polycomb complexes and that this is at least in part dependent on the association with E2F6.

Indexed as

Adenovirus E1A ProteinsAntigens, Viral, TumorCell Culture TechniquesCell LineE2F Transcription FactorsGenes, ReporterHeLa CellsHumansKidneyLuciferasesModels, BiologicalMutationOncogene Proteins, ViralPapillomaviridaePapillomavirus E7 ProteinsPlasmidsAdenovirus E1A ProteinsAntigens, Viral, TumorE2F Transcription FactorsLuciferasesoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsRecombinant Fusion Proteins

Identifiers

PMID18579589
PMCPMC2519642
OpenAlexW2053146635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.